The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate

I. Merenkova (Kyiv, Ukraine), V. Gavrysyuk (Kyiv, Ukraine), Y. Dziublyk (Kyiv, Ukraine), G. Gumeniuk (Kyiv, Ukraine)

Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Session: Moving forward in various aspects of sarcoidosis
Session type: E-poster
Number: 716

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Merenkova (Kyiv, Ukraine), V. Gavrysyuk (Kyiv, Ukraine), Y. Dziublyk (Kyiv, Ukraine), G. Gumeniuk (Kyiv, Ukraine). The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate. 716

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Alexander Vizel - 27.09.2022 12:26
I fully agree with the results of the work. Similar data were obtained in Tatarstan.
You must Login to comment this presentation.


Related content which might interest you:
Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021



One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy
Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases
Year: 2007


The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002

Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017


Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005

Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004

The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008


Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004

Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis
Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Year: 2020


The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up)
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010


Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014


Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009

High-doses glucocorticosteroid treatment in sarcoidosis patients
Source: Eur Respir J 2007; 30: Suppl. 51, 118s
Year: 2007

Follow-up of the patients with newly diagnosed sarcoidosis treated with oral corticosteroids. Features associated with chronic sarcoidosis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008

Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis
Source: Eur Respir J 2011; 38: 1145-1150
Year: 2011



Colchicine, prednisone versus no therapy in idiopathic pulmonary fibosis
Source: Eur Respir J 2006; 28: Suppl. 50, 744s
Year: 2006

The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002

Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 15s
Year: 2002

Treatment results using low doses of prednisolone, cyclophosphamide and extracorporeal processing of lymphocytes with prednisolone in patients with idiopathic interstitial pneumonia (IIP)
Source: Eur Respir J 2003; 22: Suppl. 45, 197s
Year: 2003